| http://www.w3.org/ns/prov#value | - At third-quarter time, Glaxo reported ???core??? EPS of 82.1p for the first nine months, with core results given exclusive of various amortisation, impairments, restructuring and other costs, and issued guidance for a 3-4% growth in core EPS for the full year.
|
